



A retrospective study on the incidence of medication-related osteonecrosis of the jaws (MRONJ) associated with different preventive dental care modalities

Christian Bacci¹ · Alessia Cerrato¹ · Elisa Bardhi¹ · Anna Chiara Frigo² · Selma Ahcene Djaballah³ · Stefano Sivoilella¹

Received: 3 May 2021 / Accepted: 21 September 2021
© The Author(s) 2021

Abstract

Purpose To assess the efficacy of different preventive dental visits and treatments in reducing the risk of medication-related osteonecrosis of the jaws (MRONJ).

Methods In this retrospective study, patients diagnosed with MRONJ were divided into 5 groups based on available data: no preventive dental visits (group 0); dental visits and compliance with recommended treatments, at the university hospital's dental clinic (group 1) or maxillofacial surgery unit (group 2), or at a private dentist's (group 3); dental visits at one of the above and noncompliance with proposed treatments (group 4); patients judged eligible by the oncologist on panoramic radiography (group 5). Patients were classified on severity of MRONJ according to the Italian SIPMO/SICMF 2.0 staging system. A descriptive analysis was performed on the results. Fisher's exact test was applied ($p < 0.05$).

Results Ninety-three patients diagnosed with MRONJ were considered for the study, but 22 were excluded due to a lack of data, leaving a sample of 71 cases. MRONJ staging was only 0 for some patients (26.92%) in group 0. In all groups, the majority of patients had stage 2 MRONJ. The proportions of cases in stage 3 were 7.69% in group 0, 18.18% in group 3, and 43.48% in group 5. Groups 0 and 3 were somewhat similar as regard MRONJ staging. Most patients in group 5 had MRONJ stage 2 or 3. No statistically significant differences emerged between the groups.

Conclusions Preventive dental care can reduce the risk of MRONJ providing patients comply with the specialist's recommendations.

Keywords MRONJ · BRONJ Bisphosphonates · Cancer · Prevention · Oral health

Introduction

Medication-related osteonecrosis of the jaw bones (MRONJ) is one of the most debated diseases in dentistry. This adverse event was initially described as bisphosphonate-related osteonecrosis of the jaws (BRONJ) [1], but since 2010, there have been reports of this condition in patients taking other

categories of drugs [2], making it necessary to rename the disease as medication-related osteonecrosis of the jaws (MRONJ), or simply ONJ [3]. The types of medication most frequently associated with ONJ contain two pharmacological agents [4]: antiresorptive drugs, including oral or intravenous bisphosphonates (BPs); and receptor activator of nuclear factor kappa-B ligand (RANK-L) inhibitors such as denosumab and antiangiogenics [5, 6]. The latter are monoclonal antibodies that block the receptor or growth factor (bevacizumab), and small molecules that take effect by binding the tyrosine kinase receptor (sunitinib and sorafenib) [7].

The sequence of events leading to the onset of MRONJ and the prevalence of the condition are still not completely clear [8]. Two classification systems are used in Italy nowadays to stage the disease: the AAOMS [3]; and the SICMF-SIPMO [4, 9]. Both classifications stage MRONJ on the

✉ Christian Bacci
christian.bacci@unipd.it

¹ Section of Clinical Dentistry, Department of Neurosciences, University of Padova, Via Giustiniani, 1, 35128 Padua, Italy

² Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padua, Italy

³ UOC Oncology 3, Veneto Institute of Oncology IOV, IRCCS, Padua, Italy

Table 1 Medication-related osteonecrosis of the jaws staging systems compared

Stage	AAOMS 2009 ³	SICMF-SIPMO 2020 ⁹
At risk category	No evidence of exposed or necrotic bone in patients who have been treated with bisphosphonates	
Stage 0	Nonspecific clinical findings and symptoms such as jaw pain or osteosclerosis, but no clinical evidence of exposed bone	
Stage 1	Exposed/necrotic bone in patients who are asymptomatic, with evidence of infection	<p>Focal ONJ</p> <p>Clinical signs and symptoms: bone exposure, sudden dental mobility, non-healing post-extraction socket, mucosal fistula, swelling, abscess formation, trismus, gross mandibular deformity, and/or hypoesthesia/paresthesia of the lips</p> <p>CT findings: increased bone density limited to the alveolar bone region (trabecular thickening and/or focal osteosclerosis), with or without signs of: markedly thickened and sclerotic lamina dura, persisting alveolar socket, and/or cortical disruption</p> <p>1A Asymptomatic</p> <p>1B Symptomatic (pain and purulent discharge)</p>
Stage 2	Exposed/necrotic bone associated with infection as evidence of pain and erythema of the region of exposed bone, with or without purulent discharge	<p>Diffuse ONJ</p> <p>Clinical signs and symptoms: same as for Stage 1</p> <p>CT findings: increased bone density extending to the basal bone (diffuse osteosclerosis), with or without signs of: prominence of the inferior nerve canal, periosteal reaction, sinusitis, formation of sequestra, and/or oroantral fistula</p> <p>2A Asymptomatic</p> <p>2B Symptomatic (pain and purulent discharge)</p>
Stage 3	Exposed/necrotic bone in patients with pain, infection, and one or more of the following: pathological fracture, extraoral fistula, or osteolysis extending to the inferior border or sinus floor	<p>Complicated ONJ</p> <p>Clinical signs and symptoms: same as for Stage 2, with one or more of the following: extraoral fistula, displaced mandibular stumps, nasal leakage of fluids</p> <p>CT findings: osteosclerosis of adjacent bones (zygoma and hard palate), pathological mandibular fracture, and/or osteolysis extending to the sinus floor</p>

basis of clinical and radiological criteria. Table 1 shows a comparison between the two classifications.

MRONJ treatment strategies may be conservative, non-surgical, or surgical [10]. Non-surgical treatment is essentially aimed at controlling symptoms, generally pending spontaneous sequestration. It involves maintaining adequate oral hygiene, regular follow-up visits, and antibiotic and antiseptic therapy. Conservative treatment is sometimes combined with ozone therapy, hyperbaric oxygen therapy, and laser biostimulation [3, 4, 11]. Surgical treatment consists in surface osteoplasty, curettage, sequestrectomy, or bone resection. Surgery was initially reserved only for advanced cases [6, 12, 13], but some authors have claimed more recently that it can be effective in the early stages of the disease as well [14–16].

Risk factors for MRONJ are both local (dental infections, tooth extractions, oral surgery, ill-fitting dentures) and systemic (number of administrations of medication; duration of medical treatments; and, in the case of BPs, type of drug, as the risk of MRONJ is higher for zoledronic acid vs. pamidronate vs. other BPs) [17].

The main target of primary prevention in patients who are to be administered drugs potentially associated with the onset of MRONJ is to achieve and maintain a state of oral and dento-periodontal health and perfect oral hygiene, thereby eliminating local risk factors [18]. It has been demonstrated that preventive dental screening and treatment reduces the incidence of MRONJ [17, 19, 20]. Appropriate preventive oral surgery and conservative endodontic and prosthetic measures have been published [21–25].

A MRONJ risk reduction pathway has also been developed, based on a multidisciplinary collaboration between oncologists, maxillofacial surgeons, and dentists [26]. A standardized approach has yet to become well established, however. Differences in the professional profiles of the specialists performing the dental screening of patients for the prevention of MRONJ might influence their outcomes, in terms of both the risk of its onset and the staging of its severity. The purpose of this retrospective study is to seek any correlation between the modality of at-risk patients' preoperative dental assessment and treatment planning and their MRONJ event and its staging.

Materials and methods

Medical records of patients who developed MRONJ between 2010 and 2019 at Padua University Hospital and the Veneto Oncological Institute were retrospectively examined. The data were obtained from the e-Health Galileo computer system (NoemaLife, Bologna, Italy). For each patient, the following data were collected: age; sex; underlying diseases; comorbidities; types, route of administration, and duration

of drug therapies; if and how a dental check-up was performed before starting drug therapies; and any local risk factors (e.g., periodontal and peri-implant disease or ongoing inflammation) [12, 18]. Data were also collected regarding the site of osteonecrosis, symptoms, SICMF-SIPMO staging, the treatment administered, and the outcome of this treatment.

The inclusion criteria were as follows: a previous intake of drugs associated with a risk of MRONJ and a diagnosis of MRONJ according to SICMF-SIPMO [9] recommendations; and availability of the data of interest. The exclusion criteria were as follows: previous head and neck radiation therapy, and unavailability of the data of interest.

Patients were divided into 6 groups, by modality of dental screening and treatment: Group 0 included patients who did not have a dental visit prior to being treated with the drug associated with a risk of MRONJ; Group 1 included patients preventively examined by dentists at the regional reference center for oral bone diseases (Padua University's Dental Clinic), who were staged strictly according to the SICMF-SIPMO recommendations, and who adhered to the recommended treatments; Group 2 included patients who were preventively examined by specialists at Padua University's Maxillofacial Surgery Units, and who adhered to the recommended treatments; Group 3 included patients who had a preventive dental check-up performed by their own dentists, and who adhered to the recommended treatments; Group 4 included patients who had a preventive dental visit with one of the previously mentioned specialists, but did not comply with the proposed treatments; and group 5 included patients who did not have a preventive dental visit, but who had been judged eligible for antiresorptive therapy by the treating oncologist based on a panoramic radiograph and a radiologist's report.

The study protocol complied with the Declaration of Helsinki and was approved by the Ethics Committee for Clinical Trials (CESC) at Padua University Hospital (n°8628 10.02.2021).

Statistical analysis

Since this is a retrospective study, a descriptive statistical analysis was performed on the data collected, using SAS 9.4 (SAS Institute Inc., Cary, NC, USA). Fisher's exact test was used ($p < 0.05$).

Results

Ninety-three patients diagnosed with MRONJ were considered for the study, but 22 were excluded due to a lack of data, leaving a sample of 71 eligible patients: 50 females (70.42%) and 21 males (29.58%), with a mean age of 68.7 years (SD

Table 2 Mean, minimum, maximum, median, and quartile ratings for the study population's age, number of treatment cycles, and duration of therapies

No. of patients	Variable	Mean	Minimum	Maximum	Median	Lower quartile	Upper quartile
71	Age (years)	68.7	44.0	90.0	70.5	61.5	78.0
71	Duration of therapy (months)	33.9	1.0	300.0	18.0	11.0	31.0
65	Bisphosphonates (cycles)	34.2	2.0	360.0	19.0	8.0	28.0
6	Denosumab (cycles)	14.7	1.0	34.0	12.0	7.0	25.0
25	Bisphosphonates switched to Denosumab (cycles)	21.5 BP 13.6 D	3.0 BP 1.0 D	67.0 BP 34.0 D	21.0 BP 11.0 D	6.5 BP 6.0 D	26 BP 17.5 D

Table 3 Patients' MRONJ staging according to the SICMF-SIPMO criteria

Stage	No. of patients	%
1	18	25.35
2	39	54.93
3	14	19.72

Table 4 Patient distribution by preventive dental screening modality

Preventive dental screening modality	No. of patients	%
Group 0	26	36.62
Group 1	2	2.82
Group 2	4	5.63
Group 3	11	15.49
Group 4	4	5.63
Group 5	24	33.80

7 years). Patients had received a mean 20.53 cycles of therapy with zoledronate (4 mg once a month). Twenty-five patients (35.21%) switched from zoledronate to denosumab, receiving a mean 13.6 cycles of therapy (120 mg once a month). The reasons for the switching were bone progression or toxicity to zoledronic acid (e.g., renal failure). Sixteen patients (22.53%) were also treated with bevacizumab iv. (mean 7.5 mg/kg every 2/3 weeks) (Table 2).

The site of MRONJ was the maxilla in 24 patients (33.80%), the mandible in 44 (61.97%), and both jaws in 3 (4.23%). Patients were classified as SIPMO SICMF MRONJ Stage 1 in 25.35% of cases, Stage 2 in 54.93%, and Stage 3 in 19.72% of cases (Table 3).

The 71 patients in our study population were grouped as shown in Table 4, and the staging of MRONJ in each group of patients is shown in Table 5. As for their treatment, 51 patients (71.83%) were given antibiotics, 46 (64.78%) took painkillers, and 62 (87.32%) only used antiseptic therapy. Resection of osteonecrotic tissue was performed in 27 cases (38.02%), while spontaneous sequestration of the osteonecrotic area occurred in 9 (12.67%). Biopsy of the necrotic bone was performed in 24 cases, and aggregates

Table 5 Correlation between MRONJ staging and dental screening modality groups, with and Fisher's exact test result

Prevention by stage				
Prevention				
Groups	Stage 1 (n cases, %)	Stage 2 (n cases, %)	Stage 3 (n cases, %)	Total
0	7 (26.92)	17 (65.38)	2 (7.69)	26
1	0 (0.00)	2 (100.00)	0 (0.00)	2
2	1 (25.00)	3 (75.00)	0 (0.00)	4
3	3 (27.27)	6 (54.55)	2 (18.18)	11
4	2 (50.00)	2 (50.00)	0 (0.00)	4
5	4 (17.39)	9 (39.13)	10 (43.48)	23
Total	17	39	14	71

of actinomycetes were identified at histology in 13 cases (54.17%) [27]. Following conservative or surgical treatments, 40 patients (56.33%) went into remission of their MRONJ, 28 (39.43%) relapsed, and the disease developed at a new site in 3 (4.22%). It was impossible to collect MRONJ treatment outcome data for 11 patients who died of their underlying disease.

Discussion

The diagnosis of MRONJ is based on patients' medical history, previous drug intake, and clinical and radiographic signs [28, 29]. MRONJ is a relatively recently identified disease, and this explains why the numerous studies conducted have reported very different prevalence rates, natural histories, and treatment proposals. Regarding the prevalence of MRONJ, it is also necessary to distinguish between cancer patients, for whom the risk ranges from 0.2 to 6.7%, and non-cancer patients, whose prevalence is relatively low (0–0.4%)³.

The reported average age of patients with MRONJ is around 70 years old [30] (and it was 68.7 [SD = 7 years] in our sample). The disease occurs twice as often in the mandible as in the maxilla [31] (and in our sample, it affected the

mandible in 44 cases, the maxilla in 24, and both jaws in 3 patients). There are discordant data regarding the prevalence of MRONJ by sex, but it seems to affect females more than males [32]. Here again, our sample reflects those published in the literature, with females (70.42%) more affected than males (29.58%).

In all the proposed protocols for managing MRONJ, prevention is the key factor. It has always been the most effective approach, not only to reduce the risk of the disease's onset, but also to facilitate its early diagnosis, make the disease less disabling, and improve patients' quality of life [14].

The aim of primary prevention is to eliminate local risk factors, i.e., all oral and dental disease, to restore and maintain a good state of oral health, and to prevent the onset of adverse events [14]. One of the first studies dealing with MRONJ prevention, published in 2009, demonstrated a 33% reduction in the incidence of MRONJ with appropriate preventive dental treatments [22]. Other authors reported a 50% reduction in the risk of developing MRONJ in patients who had a preventive dental check-up compared to those who did not [20]. Findings in the present study are comparable for the patients who did not have a check-up with an oral cavity specialist (i.e., 50 patients in group 0, and 5 vs. 21 belonging to groups 1–2–3–4) [33]. A meaningful reduction in the risk of MRONJ among multiple myeloma patients treated with BPs was confirmed if preventive measures had been adopted [17]. In our sample, MRONJ was observed in 3/21 patients (14.2%) who started BP treatment at a time before the risk of MRONJ had come to light; 2/20 patients (10%) who started taking BPs without any preventive dental check-up; and none of the patients whose BP therapy started only after preventive dental care measures (0%) [17].

The risk of developing MRONJ varies, depending on the type of drug prescribed, the cumulative dose, and the duration of the treatment, as well as concomitant risk factors, and the patient's oral health. Physicians prescribing drugs associated with MRONJ should inform patients and their dentists about the type of drug to be administered, the dosage, the frequency of administration, and the related risk of adverse events. The dentist should then be able to identify the teeth with an uncertain prognosis before a patient's drug therapy starts. Once their therapy has begun, dentists need to distinguish between which dental treatments are indicated (associated with a low risk of developing MRONJ, and useful for its prevention), possible (associated with a low risk of developing MRONJ, but unable to prevent it), or contraindicated (associated with a risk of developing MRONJ, and not essential).

According to the literature [34], zoledronic acid is the drug most involved in the onset of MRONJ. In our sample, zoledronic acid was the culprit in 80.28% of cases (57 patients), followed by alendronate in 4.22% of cases (3 patients), ibandronate and neridronate in 4.22% of cases each (3 patients each), and pamidronate in 1.40% (1 patient). These data are in

line with previous studies [35, 36]. The patients in our sample had received a mean 20.53 injections of zoledronic acid (4 mg, once a month), corresponding to a typical treatment lasting for almost 2 years. The risk of developing MRONJ as a result of taking antiresorptive (e.g., denosumab) or antiangiogenic (e.g., bevacizumab) medication appears to be lower than for iv. BPs because the former have a shorter half-life (e.g., 20 days for bevacizumab) and do not accumulate in the bone.

The aims of the present study were to assess the efficacy of preventive dental care, but also to establish whether clinicians conducting preventive dental visits can play a role in reducing or increasing the risk of MRONJ. Various figures were involved, namely the dental team at Padua University's Dental Clinic (a regional reference center for oral bone diseases) and Maxillofacial Surgery unit, patients' own dentists, and the oncologist prescribing the drugs associated with the risk of MRONJ (who relied on dental X-rays). Patients who did not have a preventive dental visit and those who did, but failed to comply with the specialist's recommendations, were also examined.

Most of the patients who developed MRONJ had not had a dental check-up before starting therapy with drugs associated with the risk of MRONJ (36.62%), confirming the association between the onset of MRONJ and the lack of a preventive dental visit. Much the same percentage of patients (33.80%) developed MRONJ after having their dental health checked not by a dentist or maxillofacial surgeon, but by a medical oncologist, who relied on a radiographic image and a radiologist's report. This comes as no surprise, given the well-known importance in the onset of MRONJ of conditions that X-rays are unable to reveal, such as tropism of the mucous membranes, the patient's oral hygiene, or the fit of removable prostheses [8]. Patients who had not had any preventive dental visit and those assessed by their treating oncologist presented with more severe osteonecrosis (more cases of MRONJ in stages 2 and 3 according to the SICMF-SIPMO criteria).

A very small number of patients with MRONJ (2.82%) had been previously examined at the Dental Clinic where the SICMF-SIPMO's "Clinical—Therapeutic Recommendations on Osteonecrosis of the Jaw Bones (MRONJ) associated with drugs and its prevention" [9] were strictly followed. A slightly larger number of patients (5.63%) had been previously examined at the Maxillofacial Surgery Unit. The frequency of patients with MRONJ was 3–7 times higher in the case of preventive visits conducted by a general dentist (15.49%).

None of the patients previously seen by a dental specialist (hospital dentist, maxillofacial surgeon, or private dentist) developed MRONJ stage 3 (5 patients had stage 2 disease, and one had stage 1), while patients who had a preventive visit with their own dentist developed MRONJ stage 3 in 18.18% of cases (2 patients), stage 2 in 54.55% (6 patients), and stage 1 in 27.27% (3 patients) of cases.

In group 0 (no preventive dental visits), 7.69% of patients (2 patients) developed MRONJ stage 3, while in

group 5 (patients assessed by their oncologist), 43.48% of patients (10 patients) developed MRONJ stage 3.

Based on the data emerging from this study, patients preventively examined by experienced dentists or maxillofacial surgeons have a much lower risk of developing MRONJ, and any cases that do occur are usually milder (in stages 1–2). It should be emphasized, however, that our results were not statistically significant.

Multiple healthcare professionals—dentists, physicians, oral oncologists, maxillofacial surgeons, and others involved in a patient's care—can play a part in the prevention of MRONJ [25]. An ideal MRONJ risk reduction pathway should aim to enable a patient's prompt access to high-quality preventive dental treatment and facilitate their access to local services for patients given some drug therapies for some cancers that expose them to a higher risk of developing MRONJ [26]. It should also ensure timely and effective communication between oncologists, maxillofacial surgeons, and dentists. It would be desirable for dentists in charge of oral health in patients who are candidates for the administration of drugs potentially associated with MRONJ to be part of a team with expertise on this disease. Such an ideal path comes up against an important obstacle in the need to proceed urgently with treatment in cancer patients. For instance, the data that emerged on analyzing our group 4 (patients not adhering to treatments proposed by a dental specialist) can be largely explained by the fact that the urgency of starting the cancer treatment drug is often incompatible with dental clinic waiting times. The same may apply to patients who do not have a preventive dental visit, or whose dental health is judged by the oncologist on the strength of a panoramic radiograph, or by a general dentist ill-prepared on the matter of MRONJ prevention.

This retrospective study has significant limitations regarding the unavailability of some data and the small sample size. Our findings nonetheless suggest not only that preventive dental care is necessary, but also that it should be managed by an experienced clinician and conducted according to the latest guidelines.

Conclusions

Specialist preventive dental care has an impact in reducing the risk of MRONJ. The active collaboration of health professionals involved in the management of patients at risk or suffering from by MRONJ can help to minimize the disease's occurrence and its sequelae.

Author contribution Christian Bacci, study conception; Alessia Cerato, drafting, elaboration; Elisa Bardhi, data collection; Annachiara

Frigo, statistical analysis; Selma Ahcene Djaballah, conception, data collection; Stefano Sivoletta, supervision, critical revision.

Availability of data and material Data are available.

Declarations

Ethics approval The research was approved by the Ethics Committee for Clinical Trials (CESC) at Padua University Hospital (n°8628 10.02.2021).

Consent to participate All patients gave consent.

Consent for publication All patients gave consent.

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Ruggiero SL (2007) Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). *Clin Cases Miner Bone Metab* 4(1):37–42
2. Taylor KH, Middlefell LS (2010) Mizen KD Osteonecrosis of the jaws induced by anti-RANK ligand therapy *Br J Oral Maxillofac Surg* 48(3):221–223
3. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. *J Oral Maxillofac Surg.* 2014;72(10):1938–56. Erratum in: *J Oral Maxillofac Surg.* 2015 Jul;73(7):1440. Erratum in: *J Oral Maxillofac Surg.* 2015;73(9):1879.
4. Rosella D, Papi P, Giardino R, Cicalini E, Piccoli L, Pompa G (2016) Medication-related osteonecrosis of the jaw: clinical and practical guidelines. *J Int Soc Prev Community Dent* 6(2):97–104
5. Delmas PD (2008) Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. *J Clin Densitom* 11(2):325–338
6. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. *Lancet* 377(9768):813–822
7. Tenore G, Palaia G, Gaimari G, Brugnoletti O, Bove L, Lo Giudice R et al (2014) Medication-related osteonecrosis of the jaws (MRONJ): etiological update. *Senses Sci.* 1:147–52
8. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S,

- Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP (2015) Compston J International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. *J Bone Miner Res*. 30(1):3–23
9. Campisi G, Bedogni A, Fusco V. Raccomandazioni clinico-terapeutiche sull'osteonecrosi delle ossa mascellari (ONJ) farmacorelata e sua prevenzione (Version 2.0; July 2020)
 10. Bedogni A, Anesi A, Fior A, Bettini G, Nocini PF (2013) Microsurgical reconstruction of the mandible in a patient with Evans syndrome: a case report and review of the literature. *J Reconstr Microsurg* 29(8):545–550
 11. Rodriguez-Lozano FJ, Oñate-Sánchez RE (2016) Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents. *Med Oral Patol Oral Cir Bucal* 21(5):e595–600
 12. AlDhalaan NA, BaQais A, Al-Omar A (2020) Medication-related osteonecrosis of the jaw: a review. *Cureus*. 12(2):e6944
 13. Kim HY, Kim JW, Kim SJ, Lee SH, Lee HS (2017) Uncertainty of current algorithm for bisphosphonate-related osteonecrosis of the jaw in population-based studies: a systematic review. *J Bone Miner Res* 32(3):584–591
 14. Carlson ER (2014) Management of antiresorptive osteonecrosis of the jaws with primary surgical resection. *J Oral Maxillofac Surg* 72(4):655–657
 15. Ristow O, Otto S, Tröltzsch M, Hohlweg-Majert B, Pautke C (2015) Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ). *J Craniomaxillofac Surg* 43(2):290–293
 16. Kademani D, Koka S, Lacy MQ, Rajkumar SV (2006) Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. *Mayo Clin Proc* 81(8):1100–1103
 17. Catania G, Monaco F, Limberti G, Alessio M, De Martino I, Barile C, Fasciolo A, Baraldi A, Ladetto M, Fusco V (2016) Osteonecrosis of the jaws (ONJ) after bisphosphonate treatment in patients with multiple myeloma: decreasing ONJ incidence after adoption of preventive measures. *Dent J (Basel)* 4(4):45
 18. Di Fede O, Panzarella V, Mauceri R, Fusco V, Bedogni A, Lo Muzio L, Sipmo Onj Board, Campisi G. The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention. *Biomed Res Int*. 2018;2018:2684924
 19. Ripamonti CI, Maniezzo M, Campa T et al (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bony metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. *Ann Oncol* 20:137–145
 20. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis-Papaiaikovou E, Christoulas D, Terpos E, Bamias A (2009) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. *Ann Oncol* 20(1):117–120
 21. Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, Migliorati CA, Ristic H; American Dental Association Council on Scientific Affairs Expert Panel on Antiresorptive Agents. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. *J Am Dent Assoc*. 2011;142(11):1243–51.
 22. Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. *J Oral Maxillofac Surg* 63:1567–1575
 23. Moinzadeh AT, Shemesh H, Neiryck NA, Aubert C, Wesselink PR (2013) Bisphosphonates and their clinical implications in endodontic therapy. *Int Endod J* 46(5):391–398
 24. Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, Niepel D, Van den Wyngaert T (2019) Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. *Oral Surg Oral Med Oral Pathol Oral Radiol* 127(2):117–135
 25. American Association of Endodontists. Endodontic implication of bisphosphonate-associated osteonecrosis of the jaws. 2010. Chicago, IL: American Association of Endodontists; <https://www.aae.org/specialty/wp-content/uploads/sites/2/2017/07/bisphosphonatesstatement.pdf> (retrieved on internet on the 11th February 2021)
 26. Muthukrishnan A, Al-Ismaïl S, Bertelli G, Browne P (2017) MRONJ risk reduction pathway - 360 degree survey. *Br Dent J* 222(5):386–390
 27. Cerrato A, Zanette G, Boccuto M, Angelini A, Valente M, Bacci C. Actinomyces and MRONJ: a retrospective study and a literature review. *J Stomatol Oral Maxillofac Surg*. 2020;20:S2468–7855(20)30175–0
 28. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. *J Oral Maxillofac Surg* 62(5):527–534
 29. Campisi G, Mauceri R, Bertoldo F, Bettini G, Biasotto M, Colella G, Consolo U, Di Fede O, Favia G, Fusco V, Gabriele M, Lo Casto A, Lo Muzio L, Marciànò A, Mascitti M, Meleti M, Mignogna MD, Oteri G, Panzarella V, Romeo U, Santarelli A, Vescovi P, Marchetti C, Bedogni A (2020) Medication-related osteonecrosis of jaws (MRONJ) prevention and diagnosis: Italian Consensus Update 2020. *Int J Environ Res Public Health* 17(16):5998
 30. Lee CH, Son SH, Hong CM, Jeong JH, Jeong SY, Lee SW, Lee J, Kwon TG, Ahn BC (2018) Prevalence and risk factors of atypical femoral fracture bone scintigraphic feature in patients experiencing bisphosphonate-related osteonecrosis of the jaw. *Nucl Med Mol Imaging* 52(4):311–317
 31. Dodson TB (2015) The Frequency of Medication-related osteonecrosis of the jaw and its associated risk factors. *Oral Maxillofac Surg Clin North Am* 27(4):509–516
 32. Corraini P, Heide-Jørgensen U, Schiødt M, Nørholt SE, Acquavella J, Sørensen HT, Ehrenstein V (2017) Osteonecrosis of the jaw and survival of patients with cancer: a nationwide cohort study in Denmark. *Cancer Med* 6(10):2271–2277
 33. Vandone AM, Donadio M, Mozzati M, Ardine M, Polimeni MA, Beatrice S, Ciuffreda L, Scoletta M (2012) Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. *Ann Oncol* 23(1):193–200
 34. Fliefel R, Tröltzsch M, Kühnisch J, Ehrenfeld M, Otto S (2015) Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. *Int J Oral Maxillofac Surg* 44(5):568–585
 35. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. *J Bone Miner Res* 23(6):826–836
 36. Jadu F, Lee L, Pharoah M, Reece D, Wang L (2007) A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. *Ann Oncol* 18(12):2015–2019